Lee Myung-Shin, Kim Joo Heon, Lee Ji-Su, Yun Seok Joong, Kim Wun-Jae, Ahn Hanjong, Park Jinsung
Department of Microbiology, Eulji University School of Medicine, Daejeon, South Korea.
Department of Pathology, Eulji University School of Medicine, Daejeon, South Korea.
PLoS One. 2015 Apr 27;10(4):e0125405. doi: 10.1371/journal.pone.0125405. eCollection 2015.
High-grade (HG) bladder cancers (BCs) are genetically unstable and have an unpredictable course. The identification of prognostic factors in HG non-muscle invasive BC (NMIBC) is crucial for improving patients' quality of life and preventing BC-specific mortality. Here, we used an antibody microarray (AbM) to identify novel candidate biomarkers in primary HG NMIBC and validated the prognostic significance of the candidate biomarkers. Three pairs of tissue samples from primary HG NMIBC and normal urothelium were analyzed using an AbM kit containing 656 antibodies, and differentially expressed proteins were identified. Among the 42 upregulated and 14 downregulated proteins with statistical significance in BC tissues, CREB-binding protein and CD81 were selected as representative upregulated and downregulated candidate biomarkers, respectively. We then validated the expression of these candidate biomarkers in primary human urothelial cells and BC cell lines by western blotting and immunofluorescence assays, and the results were consistent with the AbM expression profiles. Additionally, Kaplan-Meier survival using immunohistochemical data from an independent primary HG NMIBC cohort comprising 113 patients showed that expression of the 2 biomarkers was significantly associated with recurrence-free and progression-free survival. In multivariate analysis, the 2 biomarkers remained significant predictors for recurrence-free survival. Taken together, our findings suggest that expression of CREB-binding protein and CD81 in BC tissue specimens may have prognostic value in patients with primary HG NMIBC.
高级别(HG)膀胱癌(BC)具有基因不稳定性且病程不可预测。识别HG非肌层浸润性膀胱癌(NMIBC)的预后因素对于提高患者生活质量和预防BC特异性死亡至关重要。在此,我们使用抗体微阵列(AbM)来识别原发性HG NMIBC中的新型候选生物标志物,并验证了这些候选生物标志物的预后意义。使用包含656种抗体的AbM试剂盒分析了来自原发性HG NMIBC和正常尿路上皮的三对组织样本,识别出差异表达的蛋白质。在BC组织中具有统计学意义的42种上调蛋白和14种下调蛋白中,分别选择CREB结合蛋白和CD81作为代表性的上调和下调候选生物标志物。然后,我们通过蛋白质印迹和免疫荧光测定法验证了这些候选生物标志物在原代人尿路上皮细胞和BC细胞系中的表达,结果与AbM表达谱一致。此外,使用来自113例患者的独立原发性HG NMIBC队列的免疫组化数据进行的Kaplan-Meier生存分析表明,这两种生物标志物的表达与无复发生存率和无进展生存率显著相关。在多变量分析中,这两种生物标志物仍然是无复发生存率的重要预测指标。综上所述,我们的研究结果表明,BC组织标本中CREB结合蛋白和CD81的表达可能对原发性HG NMIBC患者具有预后价值。